A5050961257- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- HIV/AIDS drug development and treatment
- Insect Resistance and Genetics
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Mechanisms and Therapy
- SARS-CoV-2 detection and testing
Tennessee Oncology
2016-2025
Sarah Cannon
2016-2025
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Sarah Cannon Research Institute
2010-2023
Brigham and Women's Hospital
2023
Harvard University
2023
Memorial Sloan Kettering Cancer Center
2023
Mayo Clinic
2023
WinnMed
2023
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR toxic effects in patients relapsed and refractory multiple myeloma.
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy targets B-cell maturation (BCMA), has potential for the treatment of multiple myeloma.
CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, durable responses at 12 months. Here, we present updated results 2 years after last patient (median follow-up [MFU] approximately 28 months), including analyses high-risk subgroups.Eligible had received ≥ 3 prior lines therapy or were double refractory to proteasome inhibitor...
Survival is poor among patients with triple-class–exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep, durable responses in heavily pretreated Download PDF of the Research Summary. In this international, open-label, phase 3 trial involving adults myeloma who had received two four regimens (including immunomodulatory agents, proteasome inhibitors,...
G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.In phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 180 μg per kilogram body weight) subcutaneously weekly, week, monthly (5 1600 kilogram) patients who had heavily pretreated...
8009 Background: Heavily pretreated patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated standard of care therapy have median overall survival (OS) ~12 months (mo). In the single-arm, phase 1b/2 CARTITUDE-1 study (NCT03548207), pts received a single infusion ciltacabtagene autoleucel (cilta-cel), CAR-T cell targeting BCMA. At final protocol-specified analysis (27.7-mo follow-up [MFU]), response rate (ORR) was 98%, 83% stringent complete (CR); 27-mo rates progression-free...
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric receptor T cell therapy. We performed post hoc analysis of single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18.1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete (CR) very good partial (VGPR). met its with low rates grade 3/grade 4 cytokine release syndrome (6.5%)...
Summary Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome immune‐effector cell‐associated neurotoxicity syndrome. As these been recently approved by regulatory...
8503 Background: Outcomes are poor in triple-class exposed RRMM patients (pts) who progress on immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), and CD38 antibodies (mAbs). Ide-cel, a BCMA targeted CAR T cell therapy, showed promising tolerability efficacy pts the phase I CRB-401 study ( NEJM2019;380:1726). We present primary safety data from pivotal II KarMMa trial of ide-cel (NCT03361748). Methods: Enrolled had ≥3 prior regimens (including IMiD, PI, mAb) were refractory to...
This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens subcutaneous (SC) decitabine in patients with low- or intermediate-1-risk myelodysplastic syndrome (MDS).Patients received 20 mg/m(2) SC per day for 3 consecutive days on 1, 2, every 28 (schedule A) once 7 8, 15 B) up to 1 year. Primary end point was overall improvement rate (OIR: complete remission [CR], partial [PR], marrow CR [mCR], hematologic [HI]). Secondary points were HI,...
BACKGROUND The prognosis of patients with higher‐risk myelodysplastic syndromes (MDS) remains poor despite available therapies. Histone deacetylase inhibitors have demonstrated activity in MDS and vitro synergy azacitidine. METHODS A phase 2 randomized, placebo‐controlled clinical trial azacitidine pracinostat was conducted who had International Prognostic Scoring System intermediate‐2–risk or high‐risk MDS. primary endpoint the complete response (CR) rate by cycle 6 therapy. RESULTS Of 102...